chronic kidney diseases, End stage kidney disease. Chronic kidney disease, stage 3 (moderate)
Conditions
Interventions
Intervention 1: Intervention Group: Children with stage 3 or higher chronic kidney disease receive RenaStart nutritional formula. The dosage is individually adjusted based on age, disease stage, and s
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Months to 18 Years
Inclusion criteria
Inclusion criteria: Willingness to voluntarily participate in the study A confirmed diagnosis of Chronic Kidney Disease (CKD) by the treating physician, at Stage 3 or higher Age 18 years or younger at the time of enrollment. (The age groups of birth to 10 years and 10 to 18 years will be evaluated separately)
Exclusion criteria
Exclusion criteria: Patients who receive Total Parenteral Nutrition (TPN) Patients with confirmed intolerance or allergy to cow's milk or any component of Renastart. Medical condition: Malabsorption disorders.Hepatic failure, Hemodynamic instability, Sepsis and other confirmed active infections. Concurrent participation in another clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Potassium Serum Level. Timepoint: at first - End of the first month, End of the second month, End of the third month. Method of measurement: Flame Photometry for measuring serum potassium levels and standard.;Phosphorus Serum Level. Timepoint: at first - End of the first month, End of the second month, End of the third. Method of measurement: Phosphorus analysis method by UV spectrophotometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum calcium level as an indicator of mineral balance during nutritional intervention. Timepoint: At baseline, end of month 1, end of month 3, and end of the study. Method of measurement: Laboratory biochemical analysis (serum calcium).;Serum sodium concentration. Timepoint: Baseline, end of month 1, end of month 3, and end of study. Method of measurement: Biochemical laboratory measurement.;Serum creatinine level. Timepoint: Baseline, end of month 1, end of month 3, and end of study. Method of measurement: Measured using standard clinical chemistry assays.;Serum albumin level. Timepoint: Baseline, end of month 1, end of month 3, and end of study. Method of measurement: Measured by routine biochemical laboratory tests.;Body weight (kg). Timepoint: Baseline, end of month 1, end of month 3, and end of study. Method of measurement: Measured using a calibrated digital scale.;Body height (cm). Timepoint: Baseline, end of month 1, end of month 3, and end of study. Method of measurement: Measured using a stadiometer.;Mid-upper arm circumference. Timepoint: Baseline, end of month 1, end of month 3, and end of study. Method of measurement: Measured using a non-stretch measuring tape. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Khazdouz
Iran University of Medical Sciences
Outcome results
None listed